Global Study of Del-desiran for the Treatment of DM1

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy

In brief

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

Key facts

Study ID
NCT06411288
Run by
Avidity Biosciences, Inc.
People needed
159
Starts
2024-05-30
Expected to finish
2026-09-01
Last updated by the study team
2026-01-22

Who can join

Age: 16 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.